D. Western Therapeutics Institute
4576
Wintest
6721
Ridge-i
5572
River Eletec
6666
Forside
2330
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.89%5.53B | -2.75%1.32B | -1.70%1.47B | 0.54%1.37B | 8.20%1.38B | 7.87%5.49B | 8.71%1.36B | 8.41%1.49B | 9.99%1.36B | 4.25%1.27B |
Cost of revenue | 1.52%4.57B | -3.46%1.07B | 1.01%1.21B | 1.58%1.15B | 7.23%1.14B | 5.10%4.5B | 4.59%1.11B | 4.09%1.2B | 8.58%1.13B | 3.23%1.06B |
Gross profit | -1.96%963.06M | 0.37%253M | -12.84%254.14M | -4.71%213.36M | 12.94%242.57M | 22.66%982.32M | 31.53%252.06M | 30.69%291.58M | 17.73%223.89M | 9.63%214.78M |
Operating expense | -5.70%774.19M | -11.09%202.51M | -0.61%196.88M | -3.77%187.82M | -6.50%186.98M | 4.82%821.03M | 20.61%227.77M | -1.95%198.1M | -0.78%195.18M | 2.22%199.98M |
Operating profit | 17.10%188.87M | 107.82%50.49M | -38.76%57.25M | -11.04%25.54M | 275.65%55.59M | 817.48%161.29M | 770.55%24.3M | 343.63%93.49M | 538.80%28.71M | 5,613.51%14.8M |
Net non-operating interest income (expenses) | -8.41%-14.79M | 2.03%-3.56M | -12.90%-3.99M | -7.84%-3.56M | -15.99%-3.68M | 8.96%-13.65M | -1.22%-3.64M | 3.07%-3.53M | 14.18%-3.3M | 18.70%-3.17M |
Non-operating interest income | 20.00%12K | 0.00%3K | 0.00%3K | 50.00%3K | 50.00%3K | 66.67%10K | 200.00%3K | 50.00%3K | 0.00%2K | 100.00%2K |
Non-operating interest expense | 8.42%14.81M | -2.03%3.57M | 12.89%3.99M | 7.86%3.57M | 16.02%3.68M | -8.93%13.66M | 1.28%3.64M | -3.04%3.54M | -14.17%3.31M | -18.67%3.17M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 72.07%-3M | 71.59%-2.76M | -867.09%-764K | 160.56%519K | 0 | -64.10%-10.75M | -1,465.12%-9.71M | -79K | -857K | 98.55%-105K |
Less:Other special charges | -72.07%3M | -71.59%2.76M | 867.09%764K | ---- | ---- | 139.46%10.75M | 450.14%9.71M | --79K | --857K | -98.55%105K |
Other non-operating income (expenses) | 22.16%3.94M | 91.19%-150K | -27.05%1.75M | -32.21%722K | 10.57%1.61M | -74.39%3.22M | -152.84%-1.7M | 67.11%2.4M | -27.15%1.07M | -77.43%1.46M |
Income before tax | 24.90%175.01M | 375.91%44.02M | -41.21%54.25M | -9.35%23.22M | 312.37%53.52M | 498.33%140.12M | -45.26%9.25M | 376.18%92.28M | 386.78%25.62M | 430.51%12.98M |
Income tax | -31.15%41.71M | -5.80%22.46M | -87.52%2.95M | -28.29%5.14M | 88.07%11.16M | 257.83%60.58M | 257.33%23.84M | 132.77%23.64M | -52.37%7.17M | -13.60%5.94M |
Net income | 67.59%133.3M | 247.84%21.57M | -25.26%51.3M | -1.98%18.08M | 501.35%42.36M | 1,125.78%79.54M | -145.51%-14.59M | 644.11%68.64M | 176.87%18.44M | 165.25%7.04M |
Net income continuous operations | 67.59%133.3M | 247.84%21.57M | -25.26%51.3M | -1.99%18.08M | 501.36%42.36M | 1,125.78%79.54M | -145.51%-14.59M | 644.10%68.64M | 176.87%18.44M | 165.25%7.04M |
Noncontrolling interests | 0 | 0 | ||||||||
Net income attributable to the company | 67.59%133.3M | 247.84%21.57M | -25.26%51.3M | -1.98%18.08M | 501.35%42.36M | 3,305.01%79.54M | -145.51%-14.59M | 644.11%68.64M | 170.93%18.44M | 154.44%7.04M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 67.59%133.3M | 247.84%21.57M | -25.26%51.3M | -1.98%18.08M | 501.35%42.36M | 3,305.01%79.54M | -145.51%-14.59M | 644.11%68.64M | 170.93%18.44M | 154.44%7.04M |
Gross dividend payment | ||||||||||
Basic earnings per share | 67.51%11.24 | 247.97%1.82 | -25.39%4.32 | -1.92%1.53 | 505.08%3.57 | 3,255.00%6.71 | -145.22%-1.23 | 632.91%5.79 | 170.59%1.56 | 153.64%0.59 |
Diluted earnings per share | 67.51%11.24 | 247.88%1.8195 | -25.37%4.32 | -1.97%1.5245 | 505.08%3.57 | 3,255.00%6.71 | -145.52%-1.2304 | 638.46%5.7888 | 170.37%1.5552 | 153.64%0.59 |
Dividend per share | 2.5 | 2.5 | ||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |